Current management of liver cancer

European Journal of Cancer, Supplement

Volumn 5, Issue 5, 2007, Pages 444-446

  Lopez, Patricia M ^a   Patel, Pruthvi ^a   Uva, Pablo ^a   Villanueva, Augusto ^a   Llovet, Josep M ^a,b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; INTERFERON; IODINATED POPPYSEED OIL; MITOMYCIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; SORAFENIB; TAMOXIFEN; VASCULOTROPIN RECEPTOR; YTTRIUM 90;

ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER NODULE; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RADIOFREQUENCY RADIATION; TREATMENT OUTCOME;

EID: 35548960023     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(07)70093-9     Document Type: Article

References (17)

1. Llovet J., Burroughs A., and Bruix J. Hepatocellular carcinoma. The, Lancet 362 (2003) 1907-1917
2. Parkin D., Bray F., Ferlay J., and Pisani P. Global cancer statistics 2002. CA Cancer J Clin 55 (2005) 74-108
3. El Serag H., and Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
4. Bruix J., Sherman M., Llovet J., et al. Clinical management on hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 35 (2001) 421-430
5. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
6. Llovet J. M, Real M.I, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
7. Llovet J., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
8. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). ASCO Proceedings 2007; LBA1.
9. National Cancer Institute website. US National Institute of Health. http://www.cancer.gov
10. Llovet J., Schwartz M., and Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25 (2005) 181-200
11. Llovet J., Fuster J., and Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30 (1999) 1434-1440
12. Arii S., Yamaoka Y., Futagawa S., et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. Hepatology 32 (2000) 1224-1229
13. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
14. Lencioni R., Allgaier H., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio- frequency thermal ablation versus percutaneous ethanol injection. Radiology 228 (2003) 235-240
15. Omata M., Tateishi R., Yoshida H., and Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology 127 (2004) S159-S166
16. Lopez P., Villanueva A., and Llovet J. Up-dated systematic review of randomized controlled trials in hepatocellular carcinoma. 2002-2005. Alim Pharmacol Ther 23 (2006) 1535-1547
17. Lo C., Ngan H., Tso W., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171